The results showed that there was no significant difference in TBIL and GGT indicators between the two groups of patients after treatment (p>0.05), while the levels of AFP, VEGF, ALT, and AST in the observation group were significantly lower than those in the control group (p<0.05), indicating that TACE combined with targeted drugs can significantly reduce the level of tumor markers in PHC and effectively improve liver function in patients. Here, VEGFA is linked to neoplasm.